To promote the transformation of research results of enterprises, the Beijing Economic and Technological Development Area (BDA) has listed 14 pilot test bases. 

In the first half of this year, the number of service projects of these 14 pilot test bases was 191, and the service contract amount exceeded 1.6 billion yuan ($247.52 million), which was more than 3.5 times that of last year.

Before a product is put into production, it has to go through a "small-scale test" and a "pilot test".

After the science and technology production passes the pilot test, the industrialization success rate of which can reach 80 percent.

As a beneficiary of the pilot base, the CSF herpes simplex virus injection developed by the BDA company Oriengene has just completed clinical phase Ib treatment not long ago.

Beijing E-Town Biomedical Park [Photo/kfqgw.beijing.gov.cn]

In addition, as an entrepreneurial company, Beijing Biottt Biotechnology Co., Ltd. has independently developed the innovative drug injection BioTTT001 recently.

To complete the pilot test of the drug, Biottt found a pilot test base for viral vector gene drugs located in the BDA.

The BDA officially launched the 2021 pilot test base certification and application this May. 

Different from previous years, the main body of application for this year's pilot test base has been expanded to the entire area of Beijing E-Town.

Colleges, universities and research institutes that have engaged in scientific and technological innovation in the BDA for over one year can file for an application.

Beijing E-Town Cell Therapy R&D Pilot Base under construction [Photo/kfqgw.beijing.gov.cn]

The BDA will focus on the development of new energy vehicles, viral vector gene medicines, third-generation semiconductor power device manufacturing. robots and other industries, to step up construction of pilot test bases.